<DOC>
	<DOCNO>NCT00697944</DOCNO>
	<brief_summary>To assess safety Ambisome 10 mg/kg/week patient preemptive treatment intensive care patient sepsis rise candida colonisation . Preemptive treatment ( i.e. , prophylactic treatment two high dos Ambisome® administer interval one week , patiens high risk develop fungal infection ) decrease incidence actual systemic infection . The incidence actual fungal infection assess directly impact patient ' survival intensive care resourches assess</brief_summary>
	<brief_title>Ambisome® Preemptive Treatment Multiple Candida Colonization Sepsis Patients</brief_title>
	<detailed_description />
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Toxemia</mesh_term>
	<mesh_term>Liposomal amphotericin B</mesh_term>
	<mesh_term>Amphotericin B</mesh_term>
	<criteria>Supportive mechanical ventilation 48 h LOD &gt; 5 ail body system Candida colonisation least one site addition digestive tract Suspected nosocomial infection antibiotic treatment Informed consent Patients treat oral systemic antifungal agent within 15 day prior inclusion Patients require treatment antifungal agent document ( proven probable ) fungal infection accord EORTC criterion Patients SAPS score &gt; 65 Patients neutropenia underwent bone marrow tar organ transplant cancer chemotherapy Blood creatinine &gt; 220 µmol/L Hemodyalysis Pregnant woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>FUNGAL INFECTION</keyword>
	<keyword>SEPSIS</keyword>
	<keyword>INTENSIVE CARE</keyword>
	<keyword>AMBISOME</keyword>
	<keyword>PREEMPTIVE TREATMENT</keyword>
	<keyword>Sepsis candida colonisation</keyword>
</DOC>